Provectus Biopharma (PVCT) Reports Q2 Loss of $0.02/Share

Provectus Biopharma (NYSE: PVCT) reported Q2 EPS of ($0.02), versus ($0.02) reported last year.

Our cash and cash equivalents were $4,891,313 at June 30, 2016, compared with $9,760,997 at March 31, 2016.

For earnings history and earnings-related data on Provectus Biopharma (PVCT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c
• Helius Medical Technologies (HSDT) Misses Q2 EPS by 31c